CD8A and neoplasm: In addition, immunophenotype categorization according to the distribution of T cells in the tumor stroma also predicts response to ICIs, as patients with an immune-inflamed phenotype (defined by high CD8+ T-cell infiltration) typically derive the most benefit from immunotherapy (10, 11).